Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2019 filed with the SEC

September 2, 2019August 16, 2022 Alterity Therapeutics

XBRL 30 June 2019 filed with the SEC

2019

Post navigation

Quarterly Cash Flow Report

Alterity Therapeutics to Present at the Janney Healthcare Conference in New York

Related Posts

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

January 22, 2024March 10, 2025

Appendix 4C – Q2 FY23 Quarterly Cash Flow Report

January 31, 2023May 23, 2023

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 30, 2024March 10, 2025

Recent Posts

Target Market Determination – Placement Offer
Target Market Determination – Broker Offer
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065